||Relevant Treatment Approaches
KIT A502_Y503dup PDGFRA H687Y
gastrointestinal stromal tumor
predicted - resistant
In a clinical study, PDGFRA H687Y was identified as a secondary mutation in a patient with gastrointestinal stromal tumor harboring primary KIT A502_Y503dup, who developed resistance to Gleevec (imatinib mesylate) (PMID: 18488160).